IDH1 and central nervous system cancer: In fact, this molecular feature upgrades a histologically low-grade IDH-mutant glioma (grade 2 by histology) to a high-grade glioma (grade 3 or 4), according to the current World Health Organisation Classification of Tumours of the Central Nervous System (5th edition, 2021) (CNS WHO5) [1].